引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 73次   下载 25 本文二维码信息
码上扫一扫!
阿司匹林联合替格瑞洛对冠心病患者PCI术后炎症因子的改善作用
陈宇,冯俊,周振宇,杨楠,乔丽娟,黄兴
0
(川北医学院第二临床医学院.南充市中心医院特需医疗科;川北医学院第二临床医学院.南充市中心医院五官科;川北医学院第二临床医学院.南充市中心医院心血管内科)
摘要:
【摘要】 目的 探讨阿司匹林联合替格瑞洛对冠心病患者PCI术后炎症因子的改善作用。 方法 选择2017年5月~2018年3月在我院接受经皮冠状动脉介入治疗(PCI)术后的冠心病患者120例以随机数表法将其随机分2组,每组各60例。观察组采用阿司匹林联合替格瑞洛双抗血小板治疗方案,对照组患者采用阿司匹林联合氯吡格雷双抗血小板治疗方案,均治疗12个月。比较两组患者术后炎症因子改善情况及1年心血管不良事件发生情况。结果 术后24 h、术后1周、术后1个月,观察组C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)、白介素6(IL-6)水平均显著低于对照组(P<0.05)。术后随访1年,观察组心血管不良事件发生率低于对照组(P<0.05)。两组患者在轻微出血事件以及药物相关不良反应发生率方面比较差异无统计学意义(P>0.05)。结论 阿司匹林联合替格瑞洛双抗血小板方案治疗PCI术后冠心病患者的临床效果显著,能有效减轻机体炎症反应,减少心血管不良事件发生,但其有可能增加出血风险,故临床应结合患者的实际病情合理选择个体化的双抗治疗方案。
关键词:  经皮冠状动脉介入治疗  冠心病  阿司匹林  替格瑞洛  氯吡格雷  炎症因子
DOI:
基金项目:四川省教育厅基金(12ZA054);南充市科学技术和知识产权局项目(16YFZJ0021)
The effects of aspirin plus ticagrelor on the inflammatory factors in patients with coronary heart disease after percutaneous coronary intervention
CHEN Yu,FENG Jun,ZHOU Zhenyu,YANG Nan,QIAO Liquan,HUANG Xin
(The Second Clinical College of North Sichuan Medical College, Nanchong Central Hospital)
Abstract:
【Abstract】 Objective To investigate the effects of aspirin plus ticagrelor on the inflammatory factors in patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods 120 patients with coronary heart disease underwent PCI from May 2017 to March 2018 in our hospital were selected, and randomly divided into the observation group(n=60) treated with aspirin plus ticagrelor for 12 months and control group (n=60) treated with aspirin plus clopidogrel for 12 months. The levels inflammatory factors and the occurrence of cardiovascular adverse events were compared. Results The levels of the CRP, TNFalpha and IL6 in the observation group were significantly lower than those in the control group at 24 hours, 1 week and 1 month after PCI(P<0.05). After one year followup, the incidence of adverse cardiovascular events in the observation group was 3.33%, which was significantly lower than that in the control group (13.33%)(P<0.05). However, there was no significant difference in the incidence of minor bleeding events and drugrelated adverse reactions between the two groups (P>0.05). Conclusion Asprin and Ticagrelor has a significant clinical effect in the treatment of patients with coronary heart disease after PCI. It can effectively alleviate inflammation and reduce the occurrence of cardiovascular adverse events, while it may increase the risk of bleeding. Therefore, clinical treatment regimen should be made combining with patients′ actual condition.
Key words:  PCI  Coronary heart disease  Aspirin  Ticagrelor  Clopidogrel  Hinflammatory factors

用微信扫一扫

用微信扫一扫